{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:00:36Z","timestamp":1777327236310,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10620-020-06392-2","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T19:02:41Z","timestamp":1592506961000},"page":"1693-1699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Use of Butorphanol as Treatment for Cholestatic Itch"],"prefix":"10.1007","volume":"66","author":[{"given":"Rachel Shireen","family":"Golpanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"6392_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000440829","volume":"33","author":"AE Kremer","year":"2015","unstructured":"Kremer AE, et al. Pathogenesis and management of pruritus in PBC and PSC. Dig Dis. 2015;33:164\u2013175.","journal-title":"Dig Dis"},{"key":"6392_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hep.510290229","volume":"29","author":"CR Gross","year":"1999","unstructured":"Gross CR, et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology. 1999;29:356\u2013364.","journal-title":"Hepatology"},{"key":"6392_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers U, et al. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60:399\u2013407.","journal-title":"Hepatology"},{"key":"6392_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","volume":"142","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142:1375\u20131390.","journal-title":"J Allergy Clin Immunol"},{"key":"6392_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaci.2019.04.005","volume":"144","author":"T Hashimoto","year":"2019","unstructured":"Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144:375\u2013380.","journal-title":"J Allergy Clin Immunol"},{"key":"6392_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","volume":"54","author":"AG Dawn","year":"2006","unstructured":"Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527\u2013531.","journal-title":"J Am Acad Dermatol"},{"key":"6392_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1213\/00000539-199408000-00025","volume":"79","author":"AG Bailey","year":"1994","unstructured":"Bailey AG, et al. Epidural morphine combined with epidural or intravenous butorphanol for postoperative analgesia in pediatric patients. Anesth Analg. 1994;79:340\u2013344.","journal-title":"Anesth Analg"},{"key":"6392_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1460-9592.2000.00447.x","volume":"10","author":"J Gunter","year":"2000","unstructured":"Gunter J, et al. Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Pediatric Anesth. 2000;10:167\u2013172.","journal-title":"Pediatric Anesth"},{"key":"6392_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0885-3924(96)00154-6","volume":"12","author":"E Dunteman","year":"1996","unstructured":"Dunteman E, Karanikolas M, Filos KS. Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain Symptom Manag. 1996;12:255\u2013260.","journal-title":"J Pain Symptom Manag"},{"key":"6392_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cld.2018.03.005","volume":"22","author":"AF Carrion","year":"2018","unstructured":"Carrion AF, Rosen JD, Levy C. Understanding and treating pruritus in primary biliary cholangitis. Clin Liver Dis. 2018;22:517\u2013532.","journal-title":"Clin Liver Dis"},{"key":"6392_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejphar.2003.08.007","volume":"477","author":"H Umeuchi","year":"2003","unstructured":"Umeuchi H, et al. Involvement of central \u03bc-opioid system in the scratching behavior in mice, and the suppression of it by the activation of \u03ba-opioid system. Eur J Pharmacol. 2003;477:29\u201335.","journal-title":"Eur J Pharmacol"},{"key":"6392_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2999(01)01588-6","volume":"435","author":"Y Togashi","year":"2002","unstructured":"Togashi Y, et al. Antipruritic activity of the \u03ba-opioid receptor agonist, TRK-820. Eur J Pharmacol. 2002;435:259\u2013264.","journal-title":"Eur J Pharmacol"},{"key":"6392_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejphar.2005.06.025","volume":"518","author":"S Inan","year":"2005","unstructured":"Inan S, Cowan A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol. 2005;518:182\u2013186.","journal-title":"Eur J Pharmacol"},{"key":"6392_CR14","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-662-44605-8_16","volume-title":"Pharmacology of itch","author":"A Cowan","year":"2015","unstructured":"Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for \u03ba opioid receptors. Pharmacology of itch. New York: Springer; 2015:291\u2013314."},{"key":"6392_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transpl. 2010;25:1251\u20131257.","journal-title":"Nephrol Dial Transpl"},{"key":"6392_CR16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/hepr.12830","volume":"47","author":"H Kumada","year":"2017","unstructured":"Kumada H, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47:972\u2013982.","journal-title":"Hepatol Res"},{"key":"6392_CR17","doi-asserted-by":"publisher","first-page":"e0178991","DOI":"10.1371\/journal.pone.0178991","volume":"12","author":"K Kamimura","year":"2017","unstructured":"Kamimura K, et al. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PloS One. 2017;12:e0178991.","journal-title":"PloS One"},{"key":"6392_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/AJP.0000000000000211","volume":"32","author":"RG Jannuzzi","year":"2016","unstructured":"Jannuzzi RG. Nalbuphine for treatment of opioid-induced pruritus. Clin J Pain. 2016;32:87\u201393.","journal-title":"Clin J Pain"},{"key":"6392_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12882-015-0043-3","volume":"16","author":"A Hawi","year":"2015","unstructured":"Hawi A, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16:47.","journal-title":"BMC Nephrol"},{"key":"6392_CR20","unstructured":"Fishbane, S., et al., Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney International Reports, 2020."},{"key":"6392_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1912770","volume":"382","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, et al. A phase 3 trial of Difelikefalin in hemodialysis patients with pruritus. New Engl J Med. 2020;382:222\u2013232.","journal-title":"New Engl J Med"},{"key":"6392_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association For The Study Of The Liver","year":"2009","unstructured":"European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237\u2013267.","journal-title":"J Hepatol"},{"key":"6392_CR23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394\u2013419.","journal-title":"Hepatology"},{"key":"6392_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cld.2012.11.006","volume":"17","author":"R Bolier","year":"2013","unstructured":"Bolier R, Elferink RPO, Beuers U. Advances in pathogenesis and treatment of pruritus. Clin Liver Dis. 2013;17:319\u2013329.","journal-title":"Clin Liver Dis"},{"key":"6392_CR25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/j.1440-1746.2012.07109.x","volume":"27","author":"MH Imam","year":"2012","unstructured":"Imam MH, et al. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150\u20131158.","journal-title":"J Gastroenterol Hepatol"},{"key":"6392_CR26","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","volume":"102","author":"P Tandon","year":"2007","unstructured":"Tandon P, et al. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102:1528\u20131536.","journal-title":"Am J Gastroenterol"},{"key":"6392_CR27","first-page":"773","volume":"6","author":"CP Di","year":"1984","unstructured":"Di CP, et al. Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra-and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol. 1984;6:773\u2013776.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"6392_CR28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","volume":"56","author":"AE Kremer","year":"2012","unstructured":"Kremer AE, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56:1391\u20131400.","journal-title":"Hepatology"},{"key":"6392_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","volume":"94","author":"CN Ghent","year":"1988","unstructured":"Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin: results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488\u2013493.","journal-title":"Gastroenterology"},{"key":"6392_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","volume":"26","author":"S Khurana","year":"2006","unstructured":"Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006;26:943\u2013948.","journal-title":"Liver Int"},{"key":"6392_CR31","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","volume":"102","author":"L Bachs","year":"1992","unstructured":"Bachs L, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992;102:2077\u20132080.","journal-title":"Gastroenterology"},{"key":"6392_CR32","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1111\/apt.14579","volume":"47","author":"G Webb","year":"2018","unstructured":"Webb G, et al. Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. Aliment Pharmacol Ther. 2018;47:1213\u20131219.","journal-title":"Aliment Pharmacol Ther"},{"key":"6392_CR33","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1111\/j.1572-0241.2003.08662.x","volume":"98","author":"J Browning","year":"2003","unstructured":"Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2736\u20132741.","journal-title":"Am J Gastroenterol"},{"key":"6392_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/hep.21553","volume":"45","author":"MJ Mayo","year":"2007","unstructured":"Mayo MJ, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666\u2013674.","journal-title":"Hepatology"},{"key":"6392_CR35","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1080\/09546634.2018.1456639","volume":"29","author":"E Boozalis","year":"2018","unstructured":"Boozalis E, Khanna R, Kwatra SG. Selective serotonin reuptake inhibitors for the treatment of chronic pruritus. J Dermatol Treat. 2018;29:812\u2013814.","journal-title":"J Dermatol Treat"},{"key":"6392_CR36","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jaad.2019.04.035","volume":"81","author":"SP Patel","year":"2019","unstructured":"Patel SP, et al. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol. 2019;81:1371\u20131378.","journal-title":"J Am Acad Dermatol"},{"key":"6392_CR37","volume-title":"Mosby\u2019s Drug Consult","author":"D Mosby","year":"2005","unstructured":"Mosby D. Mosby\u2019s Drug Consult. St Louis: Elsevier; 2005."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06392-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:47:04Z","timestamp":1696261624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06392-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["6392"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06392-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CL received consulting fees from CymaBay, Genfit, Pliant, Shire, GSK, Mirum, TARGET PharmaSolutions and Cara Therapeutics, research grants from CymaBay, Intercept, Genfit, Shire, GSK, Cara Therapeutics, TARGET PharmaSolutions, Novartis, Durect, Enanta, Genkyotex, Gilead, Alnylam, and Mitsubishi. CL is an associate editor for Liver Transplantation, committee participant at ABIM and receives royalties from Up-to-Date. GY reports grants and personal fees from Sanofi Regeneron, personal fees from TREVI, grants and personal fees from Pfizer, personal fees from Galderma, grants from Sun Pharma, grants and personal fees from Kiniksa, grants and personal fees from Menlo, personal fees from Eli Lily, grants and personal fees from Novartis, personal fees from Bellus, grants and personal fees from Leo, outside the submitted work. RSG has no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}